Libero Pharma
Develops transdermal naltrexone patches for patients with addiction, fibromyalgia and Crohn’s disease
Highlights
- New on EvolcAdded 2026-11-01
About Libero Pharma
Libero Pharma is developing tailored transdermal naltrexone patches for multiple indications, including opioid use disorder, alcohol use disorder, fibromyalgia and Crohn’s disease. Its stated focus is treatment options in psychiatric and central nervous system conditions.
The company is based in Edinburgh and was founded in 2018. Its team includes pharmaceutical and clinical drug-development leadership.
Product: A pipeline of tailored transdermal naltrexone patches for multiple medical indications.
Jobs at Libero Pharma
Leadership
- Martin Stapleton · Founder & ChairmanSource: company website
- Andrew Gardiner · Founder & CEOSource: company website
More biotech & pharma companies
Lightcast Discovery
Single-cell functional screening platform for antibody and drug discovery teams in biotech and pharma researchNew on EvolcLiminal Biosciences
Develops small-molecule therapeutics for metabolic, inflammatory and fibrotic diseases through GPCR pathwaysNew on EvolcLindus Health
Clinical development of in-licensed drug assets for biotech and pharma partners, run on an AI clinical trial platformNew on EvolcRemote-friendlyMacomics
Macrophage-directed drugs that clear large disease protein complexes, first targeting IgA nephropathy patientsNew on EvolcMaxion Therapeutics
Engineered protein therapeutics for ion channel- and GPCR-driven diseasesNew on EvolcMC2 Therapeutics
Topical dermatology products, prescription and DermoCosmetic, for psoriasis and itchy, dry or sensitive skinNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Contact Form 7High confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- BootstrapHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.